vinit6675's blog

Overview

It is anticipated that the dietary supplements market will record a compound annual growth rate of 6.85% and hit US$158,468.7 million by the end of 2025. The global market has seen a dramatic transformation from medicinal procedures to wellness management, making it an excellent growth driver for the dietary supplements market. As a business sector, healthcare contributes significantly to the world economy. The key factors driving the cost of medical care are focus on healthcare services, the emphasis on value, and rising price inflation.

Market Segmentation

The vitamin category is gradually increasing based on product form, while the acid segment depicts one of the quickest developing categories of supplements given the popularity of Omega-3-based dietary supplements. In the end-user category, as businesses have expanded their supplement range considering the high appetite for products, the healthcare product segments are growing at a fast pace. The global dietary supplements market has been split into minerals, vitamins, amino acids and proteins, blends, probiotics, and others based on the product form. The worldwide market is projected to lead the vitamin segment and is estimated at US$79,600.9 million by the end of 2025. From 2019-2025, the amino acids & protein category is expected to report the healthy growth of 7.50%. In the past couple of years, the market for protein supplements has risen.

Based on form, the market is further segmented into gummies, tablets, powders, capsules & softgels, and others. On the basis of distribution channels, the market for dietary supplements is segmented into store based and non-store based channels. The store-based channel is further segmented into supermarkets and hypermarkets and specialty stores among others.

Regional Overview

During the projected time frame, North America is anticipated to represent a major share of the dietary supplements market. In 2018, the regional market accounted for a 37.06% market share. Among the main country-level markets contributing to the development of the North American dietary supplements market are the US and Canada. During the forthcoming years from 2019 to 2025, the demand in the region is expected to register a substantial CAGR of 6.43%. The report also covers other regional markets including Asia-Pacific, Europe and the rest of the world. Because of the rising acceptance of healthy diets and the growth of the organized retail sector in the developing Asia-Pacific countries, the Asia-Pacific market holds a large share of the global market for dietary supplements.

Competitive Landscape

Considering the current businesses, the dietary supplements market has a broad scope. The market leaders have an upper hand with prevalent regulations and continue to win deals to exploit opportunities in the market. Also, regional scope and strong brand recognition among customers are the key for global players that helps them stay ahead. The market for the global dietary supplements is fragmented, seeing strong competition as a result. The study of key players in the global market for dietary supplements is covered in the market research report.  In the study, key companies active in the markets across different segments and regions are also profiled. A highly competitive environment is observed in the dietary supplements market. Key players in the industry dominate the supply chain and have concentrated on numerous strategic initiatives, such as mergers and acquisitions, product development and diversification of the portfolio.

Market Highlights

According to MRFR analysis, the global internet of things (IoT) in healthcare market is expected to register a CAGR of~25.5% from 2021 to 2027 and hold a value of ~USD 320 billion by 2027.

The global IoT in healthcare market is driven by several factors, such as increasing adoption of wearables to measure vitals regularly, rising mental and physical health awareness among the young population, growing telemedicine sector, and rising demand for remote monitoring systems. In addition, the emergence of implantable monitoring systems, ingestible sensors, and connected smart contact lenses is also creating new opportunities for the market. These monitoring and tracking systems analyze the vitals and notify the patient of the next drug dose. Moreover, the introduction of smart hospitals across the globe is generating possibilities for the deployment of IoT-based devices. This will enable medical staff to accelerate the processing of patient data, better drug and medicine management, and enhanced mobility and alertness of hospital employees, among others.

This partnership will augment the IoT-based solution deployment across hospitals and research centers for convenient processing.

Regional Analysis

North America is expected to dominate the IoT in healthcare market in 2021, owing to the presence of a large number of market players, better solution development infrastructure, high-class manufacturing facilities, and highly trained professionals. In addition, the prominent players are highly involved in the innovation of new products and keep on upgrading the existing hardware and software to provide an enriched consumer experience. Moreover, the competitors are involved in R&D activities to integrate health-based IoT solutions with smartphones and other smart gadgets for residential and commercial use. In addition, the major players are focusing on various business strategies such as product launch, collaborations, partnerships, and high investments in R&D to gain market share across the region.

Asia-Pacific is anticipated to be the fastest-growing regional market over the forecast period due to the digitization of healthcare infrastructure, rising number of investors, and growing physical fitness awareness among the young and working population. In addition, the availability of highly qualified engineers and technical experts is expected to support the development of new healthcare IoT solutions that will further augment the market growth in the near future.
Segmentation

The global IoT in healthcare market has been segmented into component, application, connectivity technology, and end-use. By component, the market has been segregated into medical devices, systems &software, and services. The medical devices are further segmented into wearable external medical devices, implanted medical devices, and stationary medical devices. In addition, systems and software are further categorized into remote device management, network bandwidth management, data analytics, application security, and network security. The services are categorized into support and maintenance services, consulting, and system integration. The medical device segment is expected to hold a considerable share of the market in 2021. Increasing the use of RFID, sensors, and other remote technologies for diagnosing and monitoring will augment the market growth in the assessed period.

Based on application, the global IoT in healthcare market has been classified as inpatient monitoring, medication management, telemedicine, clinical operations and workflow management, and connected imaging. Telemedicine held the largest segment share in 2020, owing to the rising demand for monitoring patient’s vitals remotely and offering virtual medical consultation to the individuals who require urgent assistance.

By connective technology, the global IoT in healthcare market has been classified as Wi-Fi, Bluetooth low energy, ZigBee, near field communication, cellular, and satellite. Cellular technology held the largest segment share in 2020, owing to the increasing adoption of smartphones, rising integration of healthcare applications, and growing online health consultation practices.

Key Players

Some of the key players in the global IoT in healthcare market are Koninklijke Philips N.V. (Netherlands), Medtronic (US), Honeywell Life Care Solutions (US), GE Healthcare (US), Boston Scientific Corporation (US), Cisco System Inc. (US), Microsoft Corporation (US), SAP SE (Germany), Proteus Digital Health (US), Qualcomm Incorporated (US), IBM Corporation (US), Resideo Technologies (US), Capsule Technologies (US), and Siemens Healthineers(Germany).

 

Market Highlights

Vitamin D, also referred to as calciferol, is a prohormoneor precursor of a hormone. It is a fat-soluble vitamin that is naturally present in a few foods. Vitamin D is synthesizedwhen ultraviolet rays from sunlight strike the skin.As a response to sun exposure, the human body produces vitamin D. Vitamin D intake can also be boosted through certain foods or supplements.

According to MRFR analysis, the global vitamin D testing market is expected to register a CAGR of ~6.1% during the forecast period of 2021 to 2027and is expected to reach USD ~963.6million by 2027.

Regional Analysis

The market has been divided, by region, into North America, Europe, Asia-Pacific, and the rest of the world.

North America is anticipated to holdthe largest market share owing to a large number of people opting fora vegan diet. An article published in April 2021 assessed the increasing number of people following veganism in the US. A survey found a 300% increase in vegans between 2004 and 2019.In addition, a report found a decrease in meat-eaters from 85% in 2019 to 71% in 2021. The rich sources of vitamin D include milk, eggs, meat, and fish.Thus, an increasing number of vegans in the region is anticipated to boost the number of people suffering from deficiency of Vitamin D. Moreover, a growing number of research studies utilizing vitamin D test kits is expected to propel the market growth in the region during the forecast period. Some of the current examples of ongoing clinical trials include understanding bone mineral density by checking levels of vitamin D at Arkansas Children’s Hospital and absorbance of nano liquid D3via 25(OH)D blood serum test at Inspired Life Medical Office, Minnesota. The vitamin D testing marketin North America is further categorizedinto the US and Canada.

The vitamin D testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The growth of the vitamin D market is anticipated during the forecast period owing to an increasing populationprone to vitamin D deficiency.According to an article published in The Journal of Clinical Endocrinology & Metabolism, Indian and Pakistani immigrants in southern US states develop vitamin D deficiency, rickets, and osteomalacia. Compared with Caucasians, Asians have lower serum 25-hydroxy vitamin D. Research institutes and NGOs collaborating for awareness and advancement of vitamin D status in the region are expected to increase the diagnosis rate through vitamin D testing. Organizations such as the Sackler Institute for Nutrition Science at the New York Academy of Sciences and the Bill & Melinda Gates Foundationin January and March 2017 convenedin order to assess the global prevalence of vitamin D deficiency,particularly in low and middle-income countries.The vitamin D testing marketin Asia-Pacific is expected to be the fastest-growing. The vitamin D testing marketin the rest of the worldhas been divided into the Middle East, Africa, and Latin America.

Segmentation

The global vitamin D testing market has been segmented based ontype, test, application, and end user.

The market, based on type, has been divided into kits, reagents, and instruments. The reagents segment is likely to hold the largest market share in the global vitamin D testing marketdue to its higher usage frequency.

The end user segments of the vitamin D testing market are diagnostic laboratories, hospitals & clinicsand home care settings.

Key Players

Some of the key players in the global vitamin D testing marketare bioMérieux SA(France), Abbott Laboratories (US), Beckman Coulter (US), Thermo Fisher Scientific (US), Mindray (China), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Corporation (Germany), Quest Diagnostics, Inc. (US), DiaSorin S.p.A. (Italy), Maccura (China), Bio-Rad Laboratories (US), Tosoh Bioscience (Japan), andMerck KGgA (Germany).

 

Market Highlights

Vitamin D, also referred to as calciferol, is a prohormoneor precursor of a hormone. It is a fat-soluble vitamin that is naturally present in a few foods. Vitamin D is synthesizedwhen ultraviolet rays from sunlight strike the skin.As a response to sun exposure, the human body produces vitamin D. Vitamin D intake can also be boosted through certain foods or supplements.

According to MRFR analysis, the global vitamin D testing market is expected to register a CAGR of ~6.1% during the forecast period of 2021 to 2027and is expected to reach USD ~963.6million by 2027.

Regional Analysis

The market has been divided, by region, into North America, Europe, Asia-Pacific, and the rest of the world.

North America is anticipated to holdthe largest market share owing to a large number of people opting fora vegan diet. An article published in April 2021 assessed the increasing number of people following veganism in the US. A survey found a 300% increase in vegans between 2004 and 2019.In addition, a report found a decrease in meat-eaters from 85% in 2019 to 71% in 2021. The rich sources of vitamin D include milk, eggs, meat, and fish.Thus, an increasing number of vegans in the region is anticipated to boost the number of people suffering from deficiency of Vitamin D. Moreover, a growing number of research studies utilizing vitamin D test kits is expected to propel the market growth in the region during the forecast period. Some of the current examples of ongoing clinical trials include understanding bone mineral density by checking levels of vitamin D at Arkansas Children’s Hospital and absorbance of nano liquid D3via 25(OH)D blood serum test at Inspired Life Medical Office, Minnesota. The vitamin D testing marketin North America is further categorizedinto the US and Canada.

The vitamin D testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The growth of the vitamin D market is anticipated during the forecast period owing to an increasing populationprone to vitamin D deficiency.According to an article published in The Journal of Clinical Endocrinology & Metabolism, Indian and Pakistani immigrants in southern US states develop vitamin D deficiency, rickets, and osteomalacia. Compared with Caucasians, Asians have lower serum 25-hydroxy vitamin D. Research institutes and NGOs collaborating for awareness and advancement of vitamin D status in the region are expected to increase the diagnosis rate through vitamin D testing. Organizations such as the Sackler Institute for Nutrition Science at the New York Academy of Sciences and the Bill & Melinda Gates Foundationin January and March 2017 convenedin order to assess the global prevalence of vitamin D deficiency,particularly in low and middle-income countries.The vitamin D testing marketin Asia-Pacific is expected to be the fastest-growing. The vitamin D testing marketin the rest of the worldhas been divided into the Middle East, Africa, and Latin America.

Segmentation

The global vitamin D testing market has been segmented based ontype, test, application, and end user.

The market, based on type, has been divided into kits, reagents, and instruments. The reagents segment is likely to hold the largest market share in the global vitamin D testing marketdue to its higher usage frequency.

The end user segments of the vitamin D testing market are diagnostic laboratories, hospitals & clinicsand home care settings.

Key Players

Some of the key players in the global vitamin D testing marketare bioMérieux SA(France), Abbott Laboratories (US), Beckman Coulter (US), Thermo Fisher Scientific (US), Mindray (China), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Corporation (Germany), Quest Diagnostics, Inc. (US), DiaSorin S.p.A. (Italy), Maccura (China), Bio-Rad Laboratories (US), Tosoh Bioscience (Japan), andMerck KGgA (Germany).

 

Market Highlights

According to MRFR analysis, the global host cell protein testing market is expected to register a CAGR of~5.7% from 2021 to 2027.

The global host cell protein (HCP) testing market is driven by several factors, such as developments in the biopharmaceutical field and growing R&D activities. Furthermore, the technological advancements in the HCP testing products will drive the market. Rising chronic diseases such as cancer are driving more R&D efforts to find viable treatments, contributing to market growth.

According to the International Agency for Research on Cancer (IARC), the global burden of cancer in 2020 reached19.3 million cases and 10 million cancer deaths. Furthermore, according to the American Cancer Society, by 2040, the global burden of cancer will reach 27.5 million cases and 16.3 million cancer deaths.

The industry players are focusing on new product development, obtaining product approvals from the regulatory bodies for more penetration in the global host cell protein testing market. For example, in June 2019, Cygnus Technologies (US) broadened its service offerings for HCP analysis with its Mass Spec Services, which will be able to detect and quantify HCPs. Furthermore, the key players are involved in new product launches, strategic agreements, and joint ventures to augment their market positions. For instance, in August 2019, Cygnus Technologies announced a strategic partnership with Bio-Techne (US)to quantify Chinese hamster ovary host cell proteins (CHO-HCP) on the ProteinSimple Ella immunoassay platform. Furthermore, in November 2020, Thermo Fisher Scientific (US) had collaborated with Northeastern University (US) to enhance its analytical capabilities and innovate in areas like monoclonal antibodies, gene, and cell therapies, where HCP testing is required

Segmentation

The global host cell protein testing market has been segmented into type and end user.

By type, the market has been segmented into PCR-based assays, ELISA-based assays, and others. The ELISA-based assays segment is expected to hold the largest share of the market in 2020 as it is considered the gold standard for HCP testing.

Based on end users, the market has been segmented into Contract Research Organizations (CROs), biopharmaceutical companies, and others. The biopharmaceutical companies segment held the largest segment share in 2020because of the extensive R&D efforts and company funding to develop new therapeutics and utilization of HCP testing in the process.

Key Players

Some of the key market players areEnzo Life Sciences, Inc. (US), Cygnus Technologies Inc. (US), BioGenes GmbH (Germany), Cytiva (US), Cisbio Bioassays (France), Molecular Devices (US), Thermo Fisher Scientific (US), Charles River (US), Bio-Rad Laboratories (US), and ForteBio (Pall) (US)

 

Market Highlights

The global 3D printing medical device software market is expected to register a CAGR of 17.62% during the forecast period and is expected to hit USD 657.08 million by 2027.

3D printing medical device software solutions are used to produce medical devices with the help of additive manufacturing. In 3D printing, three-dimensional medical devices are created by adding successive layers of raw materials. Medical devices are produced from a digital 3-D file like Magnetic Resonance Image (MRI) or a Computer-Aided Design (CAD). 3D printing solution is flexible, and it allows designers to make changes without the need for any additional tools. Manufacturers create medical devices matched to a patients’ anatomy. The software used in 3D printing medical devices performs several tasks such as printing, designing, analyzing, visualization, planning, and simulation.

3D printing software is used to create a computer-aided design with the help of a scanner, modeling software, and digital camera. The design created using the software can be adjusted and modified before printing. Software used in 3D printing medical devices performs several functions like printing, analysis, visualization, planning, and design. The medical industry accounts for 13% of the share of the revenue of the overall 3D printing industry. Additive’s manufacturing is used in various healthcare applications ranging from prosthetics to surgical guides to dental to physical therapy. 3D printing software offers flexibility and allows medical professionals to create patient-centric devices at a reasonable cost. Factors such as technological advancements in software solutions, a rise in demand for low-cost 3D printed medical devices and increasing demand for customized medical devices are driving the growth of the market.

Regional Analysis

The global 3D printing medical devices software market has been segmented on the basis of region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas 3D printing medical devices software market has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The European 3D printing medical devices software market has been segmented into Western Europe and Eastern Europe. The Western Europe 3D printing medical devices software market has further been classified into Germany, the UK, France, Italy, Spain, and the Rest of Western Europe. The 3D printing medical devices software market in Asia-Pacific has been segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. The Middle East & Africa 3D printing medical devices software market has been divided into the Middle East and Africa.

In 2019, the Americas led the 3D printing medical devices software market with a share of 42.16%, and this trend is expected to continue throughout the forecast period. This is due to the introduction of innovative technologies and their rapid acceptance, as well as the presence of key companies in the region. Moreover, increased research funding from private and public organizations is fueling the market growth in the region.

Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2020 to 2027. Global players are focused on collaboration and opening new offices in the region owing to the availability of talent. For instance, Materialise, a leading US-based 3D printing medical devices software has officially opened a new office in China with a focus on carrying out R&D on 3D printing software.

Furthermore, India and China have a number of startups such as think3D and Osteo3d working on the 3D printing medical devices software. These startups are offering services across the world, driving the growth of this region.

Key Findings of the Study

  • The global 3D printing medical device software market was valued at USD 657.08millionand is expected to register a CAGR of17.62% during the assessment period.
  • The Americas accounted for the largest share of the global market is majorly attributed to the introduction & rapid adoption of advanced technologies and the presence of key players in this region.
  • Based on the type, the integrated segment accounted for the largest market share of 75.5% in 2019.
  • Based on the function, the printing segment dominated the market with a value of 28.64% in 2019.
  • Based on the application, the medical imaging segment dominated the market with a value of 32.68% in 2019.
  • Based on the end user, the medical device companies segment dominated the market with a value of 37.6% in 2019.

 

Market Highlights

According to MRFR analysis, the global biopharmaceutical excipients market is expected to register a CAGR of~6.8% from 2021 to 2027and is expected to hold a value of ~USD 3,114.6 million by 2027.

The global biopharmaceutical excipients market is driven by several factors, such as increasing demand for oral formulations across the globe, rising demand for customized medicines, and an increasing geriatric population. Other factors such as increasing patients with chronic ailments coupled with growing life expectancy are driving the production of biopharmaceuticals. In addition, increasing stress, back pains, body aches, and headaches has augmented the demand for topical type formulation, accelerating the market growth.

The industry players focus on expanding their global footprint by strategic partnerships, investing in some company’s stock, acquisitions, and product launches. For instance, in February 2020, ReForm Biologics (US) partnered with Millipore Sigma (US) to commercialize excipients used in biotherapeutics. In August 2019, LBB Specialties (US) announced the strategic partnership with MEGGLE (Germany)to expand its excipient distribution channel across the US. In December 2018, Roquette (France) bought a majority stake in excipient producer Crest Cellose (India) that enabled the company to expand its product portfolio and presence in the Indian generic pharmaceutical market. Furthermore, the prominent players focus on new developments, employee satisfaction, the transformation of their research wings, and expanding their distribution network. These factors will augment the market growth and will increase the product demand in the forecast timeline.

Regional Analysis

North America is projected to dominate the biopharmaceutical excipients market due to the growing adoption of the latest drug manufacturing technologies, increasing chronic diseases, and expansion of production capabilities of the industry players across the region. In addition, high investments were made in the development of new excipient variants to advance the product portfolio. Furthermore, the key players are involved in collaborations, mergers, and R&D activities that propel market growth.   

Europe embraces the second-largest position in the biopharmaceutical excipients market due to growing investments in the pharmaceutical sector and increasing production capacity across the region. In addition, the region experienced high demands for pharmaceutical products. Moreover, countries such as Germany, Italy, the UK, France, and Spain have invested huge amounts in the manufacturing of new vaccines.

Segmentation

The global biopharmaceutical excipients market is categorized into product and formulation. Based on the product category, the market has been segregated into solubilizers & surfactants/emulsifiers, polyols and carbohydrates, and specialty excipients. The carbohydrates segment is expected to hold a considerable share of the market in 2021. Increasing R&D activities for the development of lipid and protein excipient-based corona vaccines is fueling the market demand. In addition, the high demand for carbohydrate-based medicines for the infant segment is propelling the biopharmaceutical excipient market.

Based on formulation, the global biopharmaceutical excipients market has been classified as oral, topical, and injectables. The oral segmentheld the major share in 2020 due to the easy intake procedure and availability of oral medicines throughout the hospitals and retail stores. Additionally, the demand for oral and topical formulations is accelerating due to the growing preference for on-the-go treatment and ambulatory treatment services coupled with increasing cases of trypanophobia.

Key Players

Some of the key players in the global biopharmaceutical excipients market are Merck KGaA (Germany), Colorcon (BPSI Holdings Inc) (US), BASF SE(Germany), Associated British Foods plc (UK), Signet Excipients Pvt. Ltd (IMCD) (Netherlands), Sigachi Industries Limited (Hyderabad), Spectrum Chemical Manufacturing Corp. (US), Roquette Frères (France), Clariant (Switzerland), DFE Pharma (Germany), J. Rettenmaier & Söhne Gmbh + Co Kg (Germany), and Evonik Industries AG (Germany).

 

Market Highlights

According to MRFR analysis, the global cerebral vascular stent market is expected to register a CAGR of~9.0% from 2021 to 2027.

The global cerebral vascular stentmarket is driven by several factors, such asthe rising prevalence of cerebral vascular diseases and the boominggeriatric population.According to the World Stroke Organization (WSO)’s Global Stroke Fact Sheet 2019, 13 million new cases of stroke are diagnosed globally every year, and over 80 million people who have experienced a stroke are currently living. Furthermore, according to a report published by Mayo Clinic, the US, in May 2019, the most powerful non-modifiable risk factor for incident stroke is aging, and the risk doubles every ten years after the age of 55. Around three-quarters of all strokes occur in those over the age of 65. The frequency of incident strokes in the older populationis likely to growas the number of people aged 65 years rise.

The key players are involved in new product launches, strategic agreements, and acquisitions to strengthentheir market positions. For instance,in August 2018, Boston Scientific (US) announced an agreement to acquire VENITI, Inc. (US), specializing in venous stent systems. New product approvals by the FDA are supplementing the market growth. For instance, in May 2019, Stryker (US) announced the FDA approval of its brain aneurysm stent system called Neuroform Atlas.

Regional Analysis

North America is expected to dominate the cerebral vascular stentmarket in 2021, owing to the increasing health awareness, rising cerebrovascular disorders, technological developments in healthcare applications, and the presence of key players across the region. According to the Brain Aneurysm Foundation data for 2019, an estimated 6.5 million persons in the United States have an unruptured brain aneurysm, or around one in every 50 people. Each year, about 30,000 people in the United States have a brain aneurysm rupture.       

In Europe, the increasing base of the target patient population, namely elderly persons (over the age of 65) and increasing cerebral vascular disorders in the region, are expected to drive the market growth during the study period. According to a report published in July 2020 by King’s College London, by 2047, there will be 2.5 million cases of stroke in Europe, which is a 23% increase from 2017 data.

Asia-Pacific is anticipatedto be the fastest-growing regional market in the forecast period due to factors such asincreasing awareness of clinical outcomes, large population base, rise in geriatric population, and booming cerebral vascular disorders. According to a report by University of Indonesia in November 2020, China had the highest prevalence of stroke in Asia with 1114.8/100 000 persons.

The rest of the world comprises Middle East, Africa, and Latin America. Due to the high rate of acceptance of modern medical devices and the rapid expansion of the healthcare industry in these regions, the cerebral vascular stent market is projected to be a lucrative market in the near future.  

Key Players

Some of the key players in the global cerebral vascular stentmarketareStryker Corporation (US), Boston Scientific Corporation (US), Johnson & Johnson Services, Inc. (US), Terumo Corporation (Japan), Cook Medical (US), Penumbra, Inc. (US), Medtronic plc (Ireland), Acandis GmbH (Germany), Phenox GmbH (Germany), and MicroPort Scientific Corporation (China)among others.

Market Highlights

Global Growth Hormone Deficiency Market is expected to have a market value of USD 5,243.3 Million by 2027.

Growth Hormone Deficiency (GHD) is a rare type of disorder where the pituitary gland produces an insufficient secretion of growth hormone in the body. GHD can be congenital or developed in a later stage.

Regional Analysis

Global Growth Hormone Deficiency Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Rest of the World.

The Americas is classified into North America. North America is further categorized into the US Canada and Latin America. The growth hormone deficiency market in the US is expected to hold a major share owing to the growing prevalence of growth hormone deficiency and Turner syndrome, affordability of costly hormonal therapy, and the presence of a well-established healthcare sector.

The European growth hormone deficiency market is categorized into Germany, the UK, France, Italy, Spain, and the rest of Europe. The European market is expected to be the second-largest growth hormone deficiency market. This is attributed to the rising occurrences of growth hormone deficiencies, increasing preference for growth hormones in the treatment of Idiopathic Short Stature (ISS), and rising government expenditure for the healthcare sector. According to the data suggested by the Eurostat, it is observed that among the EU member states, healthcare expenditure in France and Germany was equivalent to 11.3% of the GDP in 2017, a larger share than any other EU member state. The next highest ratio was of Sweden (11.0%).

Asia-Pacific is anticipated to be the fastest-growing market owing to the growing healthcare expenditure and the presence of a large patient pool. Growing investments in the region due to increasing demand are expected to contribute to the market growth. For instance, in March 2017, Novo Nordisk initiated a phase 3 clinical trial of somapacitan (NNC0195-0092) for Adult Growth Hormone Deficiency (AGHD) in Japan. Additionally, the rising awareness about the efficiency of growth hormone therapy in short stature is likely to increase the demand for growth hormone products in this region.
Key Players

MRFR recognizes the following companies as the Key Players in the Global Growth Hormone Deficiency Market— Novo Nordisk A/S, Eli Lily and Company, Novartis AG, and Merck KGaA, and Pfizer.

Key Findings of the Study

  • Global Growth Hormone Deficiency Market is estimated to reach USD 5,243.3 Million by 2027 at a CAGR of 4.2% during the assessment period of 2020 to 2027.
  • The US accounted for the largest share of the global growth hormone deficiency market due to high uptake rate, the presence of prominent players in the US, and product clearances from regulatory authorities.
  • Based on brand, the norditropin segment accounted for the largest market share of 32.33% in 2019.
  • On the basis of Application, the pediatric growth hormone deficiency, turner syndrome segment is expected to be the fastest-growing segment during the forecast period at a CAGR of 4.47%.
  • Based on Route of Administration, the subcutaneous segment dominated the market with a share of 43.8% in the year 2019.
  • Based on Distribution Channel, hospital pharmacies held the largest market share of 40.8% and the e-commerce website segment was the fastest-growing segment with a CAGR of 4.51%

 

Market Highlights

Epilepsy Devices Market is expected to register a CAGR of 6.56% during the forecast period and is expected to hit USD 551.2 Million by 2027.

Epilepsy Research, UK (ERUK) launched a Doctoral Training Centre (DTC) Grant Scheme with the aim of capacity building of the UK epilepsy research environment. ERUK is currently inviting applications from research institutes to apply for multiple linked Ph.D. studentships to commence 2021-2023. The National Institute of Neurological Disorders and Stroke (NINDS), a part of the USS National Institutes of Health, had appropriated USD 154 million in 2017 for research on epilepsy. The appropriation rose to USD 188 million in 2019 and is estimated to reach USD 203 million by 2020. The notable studies and research institutes that NINDS has funded include The Epilepsy 4000 (Epi4K), The Center for SUDEP Research (CSR), The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBiosS4Rx), The Channelopathy-Associated Epilepsy Research Center (CAERC), and The Epilepsy Multiplatform Variant Prediction (EpiMVP). The Epilepsy Foundation awarded USD 200,000 to two of the finalists who competed in the 9th Annual Shark Tank Competition on August 27 at the 2020 Epilepsy Pipeline Conference, Maryland, US. This included a grant of USD 125,000 to a researcher for a medical-grade smart-mattress device known as Chorus to reposition individuals and stimulate them post-seizure to prevent Sudden Unexpected Death in Epilepsy (SUDEP). Similarly, National Institute for Health Research’s (UK) Research and Innovation for Global Health Transformation (RIGHT) program has awarded USD 6.6 million to fund a project investigating epilepsy in sub-Saharan Africa in February 2020.

Segment Analysis

Global Epilepsy Devices Market has been segmented based on Product Type, Technology, Seizure Detection and Prediction Devices, and End Use.

On the basis of product type, the global epilepsy devices market is segmented into wearable devices, conventional devices, and implantable devices. The wearable devices segment is further segmented into watches, bracelets, camera devices, mattress devices, anti-suffocation pillows, and others

On the basis of technology, the global epilepsy devices market has been classified as vagus nerve stimulation, responsive neurostimulation, deep brain stimulation and accelerometry

On the basis of end use, the global epilepsy devices market has been classified as hospitals & clinics, neurology centers, home care settings, and others.

Regional Analysis

Global Epilepsy Devices Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas accounted for a larger share of the global epilepsy devices market. The large share is majorly attributed to the presence of key device manufacturers, increasing adoption of innovative software for detection of seizures, technological advancements, and high disposable income. Boost in the research funding in the European region, rising government initiatives, increasing number of patients suffering from epilepsy, an increasing number of manufacturers, improving economies, high disposable income per individual, and increased healthcare spending are resulting in the high the growth of the market in this region. The Asia Pacific region is anticipated to grow at a lucrative CAGR over the forecast period. A study funded by the Global Health Department of Sanofi and Grand Challenges Canada (grant number 0325–04) found that epilepsy affects more than 50 million people worldwide, 80% of whom live in low- and middle-income countries (LMICs). n Southeast Asia, the prevalence was moderate (6%). Around 10–12 million people with epilepsy reside in India. A significant number of patients do not receive appropriate treatment, leading to a large treatment gap. A high prevalence and incidence of epilepsy has been reported in onchocerciasis-endemic regions in Central and East Africa. There is compelling epidemiological evidence suggesting that this high burden is caused by onchocerciasis-associated epilepsy (OAE).

Key Players

MRFR recognizes the following companies as the Key Players in the Global Epilepsy Devices Market— Boston Scientific Corporation, Medpage Ltd (Easylink UK), Cerbomed GmbH (TVNS Technologies GmbH), Liva Nova (Cyberonics), Compumedics, Nihon Kohden, MC10, Empatica, Inc, Medtronic Plc, Neuropace, Inc, and Natus Medical Incorporated.

Key Findings of the Study

  • Global Epilepsy Devices Market was valued at USD 551.2 Million and is expected to register a CAGR of 6.56% during the assessment period.
  • The Americas accounted for a larger share of the global market due to the increasing adoption of treatment for epilepsy by patients.
  • Based on product type, the conventional devices segment accounted for the largest market share of 54.0% in 2019.
  • Based on technology, the vagus nerve stimulation segment dominated the global epilepsy devices market in 2019 and accounted for the largest market share with a market value of USD 252.8 million.
  • Based on seizure detection and prediction devices, the electroencephalogram (EEG) segment accounted for the largest market share of 24.0% in 2019.
  • Based on end-user, the hospitals & clinics segment dominated the global epilepsy devices market in 2019 and accounted for a market value of USD 288.3 million.

 

Pages: 1 2 3 4 5 ... » »»